PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

InsmedINSM stock hit a record high Tuesday after the Food and Drug Administration approved its drug, brensocatib, for ...

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

After Insmed (INSM) announced the FDA approved brensocatib as “Brinsupri,” making it the first approved treatment for non-cystic fibrosis ...